Navigation Links
HeartWare Selects Allen & Caron for Investor Relations and Corporate Communications
Date:3/24/2008

FRAMINGHAM, Mass., March 24 /PRNewswire/ -- HeartWare Inc. (ASX: HTW), a developer and manufacturer of miniaturized implantable heart pumps to treat advanced heart failure, today announced it has selected Allen & Caron Inc as its agency for investor relations and corporate communications. Allen & Caron Inc has offices in New York, Irvine, CA, and London.

HeartWare Chief Executive Douglas Godshall said: "There is a very significant opportunity for our miniaturized heart pump, which was designed to be the least invasive full output pump on the global market. In the U.S. alone more than 5 million patients suffer from heart failure and fewer than 3,000 donor hearts become available each year. With an international clinical trial underway that is showing very promising results and plans to commence a clinical trial in the U.S. in the first half of this year, we believe it is the appropriate time to strengthen our proactive investor relations program in order to more effectively deliver our message to the investment community in Australia, the U.S. and across Europe. We selected Allen & Caron because of its reputation and track record of successfully introducing companies to a new and broader audience of analysts, institutional investors and other investment community professionals."

Allen & Caron Partner Matt Clawson said: "HeartWare is an important new client that is bringing a much-needed advancement to the cardiovascular marketplace and we are pleased to be joining forces with management to get the word out. The company has a sound business plan and has the potential to help thousands of terminally ill patients all over the world. We are assisting HeartWare in developing and executing an investor relations program designed to communicate its business plan, improve awareness among portfolio managers and analysts and over time, enhance shareholder value as the company progresses through its upcoming milestones."

About HeartWare

HeartWare (ASX: HTW) develops and manufactures miniaturized implantable heart pumps, or Left Ventricular Assist Devices ("LVADs"), to treat patients suffering from advanced heart failure. The Company is developing the industry's smallest and least invasive pumps, which it believes will be the key to unlocking the potential of a large and underserved market. The HeartWare(R) LVAD is the only full-output pump designed to be implanted in the chest, avoiding the abdominal surgery generally required to implant competing devices. The device is currently the subject of an international clinical trial involving five investigational centers in Europe and Australia. A clinical trial in the U.S. is expected to begin in the first half of 2008.

About Allen & Caron

Allen & Caron is a full-service corporate, investor and marketing communications agency serving the needs of public companies. The Allen & Caron international client base includes emerging growth companies in a range of industry segments. The firm has offices in Irvine, California; New York City and London; maintains representation in Paris; and has an affiliate relationship with a leading investor relations firm in Italy, with offices in Milan and Rome.

For further information:

http://www.heartware.com.au US Investor Relations

Howard Leibman Matt Clawson

Director Corporate Development Partner

HeartWare Limited Allen & Caron Inc

Email: howard.leibman@heartware.com.au Email: matt@allencaron.com

Tel: +61 2 9238 2064 Tel: +1 949 474 4300


'/>"/>
SOURCE Allen & Caron Inc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Wheelchair Professionals Selects Authentidates Inscrybe Healthcare Platform to Streamline Mobility Order Processing
2. Hawaiis Premier Physician Management Company, TeamPraxis, Selects Allscripts Electronic Health Record for Statewide Deployment
3. Antares Management Solutions Selects Hyland Softwares OnBase
4. Leading Arizona Radiological Group Selects MedQuist for Speech Recognition Solution
5. Hill-Rom Selects NanoHorizons to Provide Antimicrobial Protection for Hill-Rom Products Using Nanotechnology
6. Civista Health Inc. Selects Phoenix Health Systems for Information Technology Outsourcing Services
7. DFW Partnership for Peak Health Care Performance Selects Data Aggregator for Diabetes Treatment Program
8. KISTI Selects ANSYS as a Key Supplier in Engineering Simulation
9. Non-Resident Fathers Project Selects Four National Sites for Funding to Increase Father Involvement and Improve Outcomes in Child Welfare
10. Top Nutritional Supplement Online Retailer, iHerb.com, Selects AlertSite for Web Site Performance Monitoring
11. International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as its First and Only Official Joint and Muscle Topical Cream
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , ... May 02, 2016 , ... East Los Angeles ... extractions. Currently, patients can visit Dr. Assili to receive any dental extraction treatment for ... and it expires June 30, 2016. With the lower price, patients can more easily ...
(Date:5/2/2016)... ... 2016 , ... Further establishing itself as a leader in natural pet products ... Boxes were selected from over 1,000 entrants as a winner and recipient of the ... chews for dogs are a favorite product among pet-parents worldwide, as each whimsical knobby ...
(Date:5/2/2016)... ... 2016 , ... Visceral fat, also known as “deep fat” ... and pancreas. If not properly addressed, visceral fat can lead to serious health ... Oncology and Palliative Care, warns against the dangers of visceral fat. “Just because ...
(Date:5/2/2016)... ... ... According to an American Psychological Association article, the Centers for ... age of 18. Of those who survive, many still face effects as they reach ... her new book, Lyah! Lyah! Pants on Fyah!, she shares stories from women who ...
(Date:5/2/2016)... ... May 02, 2016 , ... TeleMedCo™, a ... designed to automate and improve the rapid diagnosis, triage and admission of patients ... platform, application, and mobile experience for the first time at GENBAND’s Perspectives16 conference. ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... TapImmune,Inc. (TPIV), a clinical-stage immune-oncology company ... and vaccines for the treatment of cancer & metastatic disease, ... Growth Capital Expo to be held on May 3 ... in Las Vegas, Nevada.  The Company presentation will be ... by Dr. John N. Bonfiglio a TapImmune Board ...
(Date:4/27/2016)... MARLBOROUGH, Mass., April 27, 2016  Hologic, Inc. ... Company,s financial results for the fiscal second quarter ... share (EPS) of $0.24 increased 41.2%, and non-GAAP ... $693.3 million increased 5.8% on a reported basis, ... "We posted another good quarter, highlighted ...
(Date:4/27/2016)... , le 27 Avril 2016 ... d,affaires a progressé de +5% sur le trimestre, ... récurrentes de consommables  Croissance de +16% ... Mauna Kea Technologies (Euronext : MKEA, ... d,endomicroscopie confocale laser, annonce aujourd,hui son chiffre d,affaires ...
Breaking Medicine Technology: